An update from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) is now available.
Shanghai Haohai Biological Technology Co., Ltd. reported a slight decline in revenue and net profit for the first quarter of 2025 compared to the same period last year. Despite a decrease in R&D expenses, the company experienced a positive increase in net cash flows from operating activities, indicating a potential improvement in operational efficiency.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. operates in the biotechnology sector, focusing on the development and production of biological materials and medical devices. The company is based in China and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: -8.63%
Average Trading Volume: 566,343
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.85B
For an in-depth examination of 6826 stock, go to TipRanks’ Stock Analysis page.